Prospective clinical trials of venetoclax and hypomethylating agents for relapsed BPDCN

類似資料

• Venetoclax in the Therapeutic Strategy for BPDCN Management
  著者:: Margaux Poussard, 等
  出版事項: (2025-08-01)
• Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents
  著者:: Danielle Hammond, 等
  出版事項: (2023-09-01)
• Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens
  著者:: Abhishek Maiti, 等
  出版事項: (2020-06-01)
• Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients
  著者:: Christophe Willekens, 等
  出版事項: (2025-04-01)
• Outcome of adult acute myeloid leukemia patients with extramedullary disease and treatment with venetoclax / hypomethylating agents
  著者:: Sabine Kayser, 等
  出版事項: (2024-10-01)